Want to see AU:CYP full AI Analyst Report?
Top Page
Cynata Therapeutics Limited
(Sydney:CYP)
Select Model
Select Model
Rating:39Underperform
Price Target:
AU$0.01
▲(0.00% Upside)
Action:Downgraded
Date:09/15/26
The score is driven primarily by very weak financial fundamentals—persistent losses, continued cash burn, and a materially weakened balance sheet with negative equity in 2026. Technical indicators also point to a broader downtrend (negative MACD and price below key moving averages), despite an oversold RSI. Valuation offers limited support because profitability is negative and no dividend yield is available.
Positive Factors
Debt-free balance sheet
Zero debt reduces interest obligations and refinancing exposure, giving Cynata greater flexibility while it develops clinical programs. Although the capital base has weakened, the absence of leverage avoids an additional fixed claim on cash and may preserve strategic funding choices over the next several quarters.
Negative Factors
Persistent operating losses
Large losses relative to the revenue base show that Cynata has not yet achieved operating scale or earnings sustainability. Continued negative margins can consume capital needed for clinical development and leave future progress dependent on successfully advancing candidates toward partnering or commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero debt reduces interest obligations and refinancing exposure, giving Cynata greater flexibility while it develops clinical programs. Although the capital base has weakened, the absence of leverage avoids an additional fixed claim on cash and may preserve strategic funding choices over the next several quarters.
Read all positive factors
Cynata Therapeutics Limited (CYP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$2.68M
Dividend YieldN/A
Average Volume (3M)406.45K
Price to Earnings (P/E)―
Beta (1Y)0.86
Revenue GrowthN/A
EPS Growth13.50%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding243,454,380
10 Day Avg. Volume320,641
30 Day Avg. Volume406,454
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-8.41
Price to Sales (P/S)1.94
P/FCF Ratio-0.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$31.40M
Cynata Therapeutics Limited Business Overview & Revenue Model
Company Description
Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mesenchymal s...
How the Company Makes Money
Cynata’s ability to generate revenue is primarily tied to the development and commercialization of its cell-therapy candidates rather than ongoing product sales. Its main potential and/or historical revenue streams are: (1) collaboration and licen...
Cynata Therapeutics Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.71M | 1.89M | 2.32M | 1.65M | 7.77M |
| Gross Profit | -260.31K | 1.89M | 2.32M | 1.37M | 7.49M |
| EBITDA | -7.55M | -9.33M | -9.95M | -15.65M | -6.00M |
| Net Income | -9.09M | -9.39M | -9.74M | -14.28M | -5.45M |
Balance Sheet | |||||
| Total Assets | 1.35M | 7.20M | 8.39M | 18.99M | 26.55M |
| Cash, Cash Equivalents and Short-Term Investments | 897.42K | 5.05M | 6.21M | 16.17M | 23.80M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.75M | 1.22M | 1.17M | 2.26M | 2.59M |
| Stockholders Equity | -394.24K | 5.98M | 7.22M | 16.73M | 23.96M |
Cash Flow | |||||
| Free Cash Flow | -6.74M | -8.77M | -9.96M | -14.28M | -3.30M |
| Operating Cash Flow | -6.74M | -8.72M | -9.96M | -14.28M | -3.30M |
| Investing Cash Flow | 0.00 | -50.00K | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 2.58M | 7.61M | 0.00 | 6.72M | 210.12K |
Cynata Therapeutics Limited Technical Analysis
Neutral
0.01
Price Trends
0.01
Negative
0.08
Negative
0.20
Negative
Market Momentum
>-0.01
Negative
28.06
Positive
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CYP, the sentiment is Neutral. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.20, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 28.06 is Positive, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:CYP.
Cynata Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$2.65B | -31.95 | -10.06% | ― | 555.67% | 49.08% | |
52 Neutral | AU$16.04M | -2.16 | -247.44% | ― | -4.24% | 33.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$207.02M | -14.34 | -36.83% | ― | 51.07% | -47.63% | |
43 Neutral | AU$5.44M | -1.02 | -52.04% | ― | 32.22% | -26.53% | |
40 Underperform | AU$17.23M | -4.72 | -132.20% | ― | ― | -200.00% | |
39 Underperform | AU$2.68M | -0.29 | -607.23% | ― | ― | 13.50% |
* Healthcare Sector Average
AU:CYP
Cynata Therapeutics Limited
0.01
-0.21
-95.11%
AU:1AI
Living Cell Technologies
0.01
0.00
0.00%
AU:MSB
Mesoblast Limited
2.04
-0.55
-21.24%
AU:OCC
Orthocell Ltd
0.76
-0.70
-47.95%
AU:TRP
Tissue Repair Ltd
0.09
-0.19
-67.86%
AU:CMB
Regeneus Ltd.
0.55
0.05
10.10%
Cynata Therapeutics Limited Corporate Events
Cynata Options Lapse, Streamlining ASX-Listed Capital Structure
Sep 10, 2026
Cynata Therapeutics Limited has updated the market on changes to its capital structure following the expiry of several tranches of listed options. On 10 September 2026, a total of 3 million options with exercise prices ranging from $0.40 to $0.60 ...
Cynata narrows loss but trial setbacks and cash squeeze deepen going-concern risk
Aug 31, 2026
Cynata Therapeutics reported a net loss of $9.1 million for the year to 30 June 2026, slightly improved from the prior year, as revenues fell and cash reserves dropped to $0.9 million. The group moved from net assets to net liabilities and recorde...
Cynata Plans ASX-Quoted Share Placement to Raise Capital
Aug 25, 2026
Cynata Therapeutics Limited has notified the ASX of a proposed issue of up to 2,000,000 ordinary fully paid shares. The placement, scheduled for issue on 30 October 2026, is intended to be quoted on the ASX in line with listing rule requirements, ...
Cynata Slashes Costs After Key Cell Therapy Trials Miss Efficacy Targets
Jul 30, 2026
Cynata Therapeutics reported June quarter results marked by disappointing efficacy outcomes in two key Cymerus-based cell therapy programs, despite acceptable safety profiles. The Phase 2 trial of CYP-001 in high-risk acute graft versus host disea...
Cynata Options Lapse Clarifies Future Equity Structure
Jul 9, 2026
Cynata Therapeutics Limited has notified the market of the cessation of 24,445 options (CYPAE) expiring on November 20, 2028, exercisable at $0.185. These securities lapsed because the conditions attached to the options were not met or became inca...
Cynata Discloses Final Director Interest as Dr Darryl Maher Departs Board
Jul 5, 2026
Cynata Therapeutics Limited has announced the cessation of Dr Darryl Maher as a director effective 6 July 2026. At the time of his departure, Dr Maher held 116,666 ordinary shares and 220,000 unlisted options exercisable at $0.185 expiring in Nove...
Cynata Slashes Costs, Axes Staff and Taps R&D Loan to Extend Cash Runway
Jul 5, 2026
Cynata Therapeutics has implemented sweeping cost-cutting measures, making all employee positions redundant, including the CEO and other key executives, and shifting management responsibility to a streamlined, largely unpaid board. The company has...
Major Shareholder FIL Limited Exits Position in Cynata Therapeutics
Jul 2, 2026
Cynata Therapeutics has received notice that FIL Limited has ceased to be a substantial holder in the company as of 30 June 2026. FIL disposed of 15,526,501 common shares, removing its prior substantial holding position and altering the company...
Bioscience Fund Exits Substantial Holding in Cynata Therapeutics
Jun 23, 2026
Phillip Asset Management, acting for Bioscience Managers Translation Fund I, has ceased to be a substantial shareholder in Cynata Therapeutics after disposing of its remaining voting securities. The fund sold tranches of Cynata shares on 19 June a...
Cynata to Host Investor Webinar on Results Update
Jun 21, 2026
Cynata Therapeutics has scheduled an investor webinar for 22 June 2026, hosted by CEO and Managing Director Dr. Kilian Kelly and Chair Dr. Geoff Brooke, to provide a results update to shareholders. The company will make the webinar presentation ma...
Cynata’s CYP-004 Fails to Outperform Placebo in Phase 3 Knee Osteoarthritis Trial
Jun 19, 2026
Cynata Therapeutics reported top-line results from the University of Sydney’s Phase 3 SCUlpTOR trial of its Cymerus-derived CYP-004 cell therapy in knee osteoarthritis. The study found no safety concerns and showed substantial pain reduction...
Cynata Halts CYP-001 GvHD Trial After Phase 2 Misses Efficacy Goals
Jun 17, 2026
Cynata Therapeutics reported primary evaluation results from its Phase 2 trial of CYP-001 in high-risk acute graft versus host disease, showing no safety concerns but no significant efficacy differences versus steroid plus placebo treatment. The t...
Cynata Seeks ASX Trading Suspension Ahead of Key Clinical Trial Results
Jun 16, 2026
Cynata Therapeutics has requested a voluntary suspension of trading in its shares on the ASX, with the exchange implementing the halt under Listing Rule 17.2 pending a material announcement. The suspension is expected to remain in place until eith...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.